Last reviewed · How we verify
NCT07230496
A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE103 or LAE103 in Combination With LAE102 in Healthy Overweight/Obese Participants
Phase 1 trial testing LAE103 injection in Overweight and Obesity in 104 participants. Currently enrolling.
20 March 2028
Quick facts
| Lead sponsor | Laekna Limited |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | basic science |
| Enrollment | 104 |
| Start date | 30 December 2025 |
| Primary completion | 20 March 2028 |
| Estimated completion | 20 March 2028 |
| Sites | 1 location across Australia |
Drugs / interventions tested
- LAE103 injection — full drug profile →
- LAE102 injection in combined with LAE103 injection — full drug profile →
- Saline
Conditions studied
- Overweight and Obesity — all drugs for Overweight and Obesity →
Sponsor
Laekna Limited — full company profile →
Who can join
Adults 18 to 75, any sex, with Overweight and Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of LAE103 injection in healthy overweight/obese participants or healthy postmenopausal women. Study will also evaluate the safety, tolerability and preliminary pharmacodynamic effect of multiple dose injections in overweight/obese participants. In addition, the study will also investigate the safety, tolerability of a single-dose co-administration of LAE102 and LAE103 in healthy overweight/obese participants.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07230496
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Overweight and Obesity
Currently open trials in the same condition.
- NCT06282952 — Health Outcomes in C-Section Infants With Fecal Microbiota Transplantation · NA · recruiting
- NCT07406191 — WB-EMS Effects on Cardiometabolic Risk Factors · NA · recruiting
- NCT07313761 — A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered · Phase 1 · active not recruiting
- NCT07165431 — Effect of a Postbiotic Supplementation in Overweight and Obese Subjects: A Randomized Controlled Trial (PARABIOTICS-2). · NA · recruiting
- NCT07395973 — The Effects of a 4-week Supplementation With a Ketogenic Nutrient Mix on 24-hour Substrate Metabolism and Muscle Health · NA · recruiting
Other Laekna Limited trials
Trials by the same sponsor.
- NCT06908707 — A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE102 in Postmenopausal Women · Phase 1 · completed
- NCT06493084 — Evaluate LAE102 in Healthy and Overweight/Obese Subjects · Phase 1 · recruiting
- NCT05489744 — Human Mass Balance and Biotransformation Study of [14C]Afuresertib · Phase 1 · completed
- NCT05383482 — Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 · Phase 1, PHASE2 · completed
- NCT04851613 — Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/ · Phase 3 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07230496 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Laekna Limited
- Last refreshed: 20 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07230496.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing